Ana sayfa
Piyasalar
Grafikler ve fikirler
Algo
Haberler
Store
Aracı kurumlar
İndir
Ekonomik Takvim
Alım-satım sinyalleri
Web Terminali
Arama yapmak için
/
tuşuna basın: @kullanıcı, $sembol, ...
Ara
Giriş yap
Hesap oluştur
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
TCRX
#3154
TScan Therapeutics, Inc. Common Stock
1.0
6
-3.64%
Sektör:
Baz:
Kar para birimi:
Günlük aralık
Yıllık aralık
Günlük değişim
-3.64%
Aylık değişim
-4.50%
6 aylık değişim
-43.32%
Yıllık değişim
-48.29%
Önceki kapanış
1.1
0
Open
1.0
6
Bid
Ask
Low
1.0
6
High
1.0
6
Hacim
6
Piyasalar
ABD hisse senetleri
Sağlık hizmetleri
TCRX
Open full chart
Financials
Overview
Rapor
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
49.09 M
52.31 M
52.31 M
52.47 M
52.47 M
—
Valuation ratios
Enterprise value
642.94 M
324.42 M
74.28 M
71.26 M
132.55 M
602.51 M
Price to earnings ratio
-9.4
-2.67
-1.28
-1.34
-1.64
-6.93
Price to sales ratio
38.47
120.9
38.08
26.26
27.69
212.92
Price to cash flow ratio
4.38
3.07
1.38
1.41
1.75
7.61
Price to book ratio
0.64
1.41
0.17
0.21
0.29
2.08
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.09
0.1
0.1
0.12
0.14
0.46
Return on equity %
0.13
0.15
0.16
0.21
0.25
0.77
Return on invested capital %
—
—
—
—
—
—
Gross margin %
100
100
100
100
100
400
Operating margin %
3 109.82
5 520.6
1 669.74
1 256.6
1 475.59
9 922.53
EBITDA margin %
—
—
—
—
—
—
Net margin %
2 849.09
5 384.81
1 571.95
1 201.3
1 422.14
9 580.2
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
9.56
8.14
8.55
7.06
6.44
30.19
Inventory turnover
—
—
—
—
—
—
Asset turnover
0
0
0.01
0.01
0.01
0.03
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.09
0.09
0.1
0.11
0.12
0.41
Long term debt to total equity ratio
0.13
0.13
0.15
0.18
0.23
0.69
Per share metrics
Operating cash flow per share
0.24
0.24
0.29
0.26
0.25
1.04
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
2.28
2.59
1.94
1.68
1.42
7.63
Net current asset value per share
2.31
2.61
1.97
1.7
1.45
7.73
Tangible book value per share
1.93
2.15
1.62
1.36
1.11
6.24
Working capital per share
2.07
2.29
1.74
1.46
1.22
6.72
Book value per share
1.93
2.15
1.62
1.36
1.11
6.24
Haberler
TScan completes enrollment in trial cohort, receives FDA clearance
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Beats Revenue Estimates
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Roivant Sciences Ltd. (ROIV) Reports Q3 Loss, Misses Revenue Estimates
Tracking Baker Brothers Portfolio – Q3 2025 Update (NASDAQ:INCY)
Tscan Therapeutics: BTIG bestätigt "Neutral"-Rating nach ASH-Event
Tscan Therapeutics stock holds Neutral rating at BTIG after ASH event
TScan to host KOL event discussing updated ALLOHA trial data
Tscan Therapeutics: Morgan Stanley stuft Aktie wegen Studienverzögerungen herab
Morgan Stanley downgrades Tscan Therapeutics stock on delayed trials
Tscan Therapeutics: EPS übertrifft Schätzungen um 0,06 $ - Umsatz besser als erwartet